Nivolumab, an anti-PD-1 mAb, decreased the frequency of Treg population and increased the number of CD8+ T lymphocyte infiltration in patient-derived colorectal cancer xenografts.246. This evidence concerns the gene PDCD1 and colorectal cancer.